The April 2026 federal rescheduling order has fractured the American cannabis landscape. By moving medical marijuana to Schedule III while leaving adult-use in Schedule I, the government has created a stark legal and financial divide—offering immediate tax relief to medical operators while leaving recreational businesses stranded in the cold.
Minnesota’s new 2026 Cannabis Omnibus Bill dramatically alters the state’s marketplace. By introducing a “Ratio Hemp-Infused Cannabis Product” category, the legislation effectively doubles individual serving limits to 10 mg of THC and quadruples retail packaging caps to 200 mg. Discover how these updated milligram caps, along with the newly established Cannabis Macrobusiness licenses and adjusted social equity funding rules, are reshaping the industry landscape for local hemp manufacturers and retailers.
THC and CBD are primary cannabinoids that interface with the endocannabinoid system to regulate homeostasis. THC provides euphoria and manages nausea or pain, while CBD offers non-intoxicating benefits for epilepsy, anxiety, and inflammation through complex pathways.